Chronos Archive seal

Review checklist: Flannery O'Connor (HR-ML046)

All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments

Everything a reviewer needs to judge, gathered from the record. Release status: draft.

Review status

ReviewStatusReviewerDateNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the EULAR/ACR scoring, the indication for kidney biopsy and the class III result, the choice of mycophenolate with belimumab over a calcineurin inhibitor, the glucocorticoid taper, the contraception choice, and the bone and vaccination plans.
provenance reviewnot_startedHer lupus, her father's lupus, the ACTH and later steroid treatment, the hip disease and crutches, the 1964 surgery, and her death are documented from a medical society journal article drawing on her letters and the standard biography, PBS, the New Georgia Encyclopedia, a Scribner reference biography, and a medical humanities essay. Avascular necrosis and an early malar rash are physicians' retrospective interpretations (R). Her mother appears only in a documented claim; no relative is quoted or makes any decision.
safe messaging reviewnot_startedNo behavioral-health diagnosis; mild depressive symptoms at diagnosis are screened and improve; the concealment of her diagnosis within her family is recorded factually without judgment; death recorded without detail.

Judgment calls (dossier editorial resolutions)

  1. Index age and dates. Index age 25. The brief suggested an index date in December 1950 or early 1951. Visits in 2026 can only map to January through October of a true year; with a shift of 75 the episode would fall from January 1951 onward, when the sources place her in hospital in Milledgeville and Atlanta and then on ACTH, and the synthetic outpatient visits would contradict that. A shift of 76 instead maps the index visit on April 13, 2026 to April 13, 1950, when she was 25, in the year the sources say her joint pain began and rheumatoid arthritis was suspected, and before the December 1950 illness in which lupus was diagnosed. The synthetic date of birth is March 25, 2001 (shift 76 years), keeping her birthday. The other visits (April 22 and 29, June 15, July 27, October 5, and October 26, 2026) map to the same days of 1950, all before that December. The index age of 25 matches the brief.
  2. Diagnosis date. Sources date her diagnosis to 1950 (PBS, New Georgia Encyclopedia, Hektoen), late 1950 in Atlanta (Pharos, Scribner), or January 1951 (a search summary of a Georgia Historical Society page, not used). The timeline records it as "1950, by December," approximate. A disability-studies article seen in search said a specialist told her in July 1952; it was not fetched and is not used.
  3. The 1964 operation. Sources describe it as surgery for a fibroid tumor (PBS, New Georgia Encyclopedia), removal of a benign abdominal tumor (Scribner), or a hysterectomy (Pharos). The claim says abdominal surgery for a bleeding fibroid and notes the hysterectomy in its interpretation; it is later than the episode and not used.
  4. Avascular necrosis. Crutches, hip pain, and her letter that her doctors blamed the steroid drugs for her "bone disintegration" are documented (D). The label avascular necrosis of the femoral head, and a possible effect on the jaw, are physicians' retrospective interpretation (R, probable); an early malar rash and Jaccoud arthropathy are R, possible. None is used as a finding in the modern episode, which instead keeps glucocorticoids low, starts a steroid-sparing drug at once, measures bone density, and teaches her to report hip pain.
  5. Teaching contrast: disclosure. Her mother chose not to tell her the diagnosis, and she learned it from a friend in 1951 (source 1, citing the biography). This is recorded as a documented claim linked to a later timeline event, without judgment. The synthetic episode tells her the diagnosis directly at the first chance, with teach-back and a written copy, and her advance directive asks that she always be told first. No modern statement, decision, or health fact is attributed to her mother or any other relative; her father's lupus appears only as documented family history, and the modern notes say only that she knows he had lupus.
  6. Treatment choices. Synthetic: ISN/RPS class III (A) lupus nephritis with activity 6 and chronicity 1, so that the episode teaches proliferative nephritis with a good prognosis; pulse methylprednisolone, prednisone tapered from 30 mg to 5 mg by six months, mycophenolate 2 g a day, and belimumab, which she chose over voclosporin (both are add-on options in EULAR 2023 and ACR 2024); hydroxychloroquine 300 mg, 5 mg/kg at 60 kg; losartan. Judgment call: Pneumocystis prophylaxis was discussed and not started, because the prednisone dose falls below 20 mg within six weeks and sulfonamides are avoided in lupus; a reviewer may prefer atovaquone. The responses (a ratio falling from 1.8 to 0.9 g/g at three months and 0.35 at six months) are synthetic and on the favorable side.
  7. Contraception and pregnancy. She chose a levonorgestrel intrauterine system before mycophenolate; with negative antiphospholipid antibodies estrogen was also an option. The six-month visit gives a pregnancy plan (azathioprine in place of mycophenolate, losartan stopped, hydroxychloroquine continued, anti-Ro and anti-La tests, low-dose aspirin from 12 weeks), all synthetic and not linked to her life.
  8. Focused visits. The four chronic-care follow-ups (diagnosis with the consultation, the biopsy result and treatment start, three months, and six months) are documented as focused visits on the 2019 EULAR/ACR criteria, EULAR 2023, ACR 2024, the AAO, ACR vaccination, ACR glucocorticoid-induced osteoporosis, and ACR reproductive health guidelines, the mycophenolate and belimumab labels, and the CMID kidney monograph. The rheumatology blood counts between visits are reported in prose, not as observations; the hepatitis, HIV, pregnancy, and urine culture results are reported in prose. One protocol deviation is recorded: potassium and creatinine two to four weeks after starting losartan were missed, found normal at the sick visit at seven and a half weeks, with the corrective action recorded.
  9. Sick visit. An unscheduled sick visit on June 15, 2026 (true frame June 15, 1950) for cystitis on mycophenolate, belimumab, and prednisone. It teaches the low threshold for culture and treatment on immunosuppression, a seven-day nitrofurantoin course, avoiding sulfonamides in lupus, not measuring urine protein during infection, and telling infection apart from a nephritis flare. It insinuates no undocumented real diagnosis.
  10. Preventive visit. An adult preventive visit (age 25, so `preventive_adult`) on October 5, 2026 (true frame October 5, 1950). Synthetic judgment calls: yearly cervical screening while immunosuppressed (a judgment based on the higher risk on immunosuppression, not a USPSTF interval); HPV and hepatitis B vaccination in childhood; the advance directive names no real person.
  11. Consultation. The rheumatology referral and the consultation by Rafael Okonjo-Strand, MD (a fictional consultant), on the day of the second visit, are S. The consultant answers the seven referral questions with what the record shows happened afterwards: classification by the 2019 criteria; a kidney biopsy, which showed class III; pulse and tapering glucocorticoids, mycophenolate with belimumab, hydroxychloroquine, and losartan; vaccination before immunosuppression; an intrauterine system before mycophenolate; DXA, vitamin D, avascular necrosis counseling, and a baseline eye examination; and family-history counseling.
  12. Name. The apostrophe in O'Connor is kept exactly. The generators write it as `'` in the C-CDA and HTML and as a plain apostrophe in the notes; the cross-case name check matched it correctly. The alias "Mary Flannery O'Connor" appears in no other record; "O'Connor" alone appears in other records only as the surname of unrelated authors and is not used as an alias.
  13. Other people. The friend from whom she learned the diagnosis, the Atlanta kidney specialist, and her writing teachers are not named; no living person is named. The supporting people in the social history are unnamed and make no decisions.
  14. O'Connor died in 1964, so the recent-death review rule does not apply. Ordinary clinical, provenance, and safe-messaging reviews remain required.

Protocol deviations

Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.

VisitMeasureIntervalWhat happened
2026-07-27
Progress note 05 (C-CDA)
Potassium and creatinine after starting losartan2 to 4 weeks after startingMissed, a deviation from the protocol: the check due two to four weeks after losartan was started was not drawn, because the standing rheumatology orders were for blood counts only. The first potassium, at the sick visit seven and a half weeks after starting, was 4.6 with creatinine unchanged at 0.8, so no harm resulted. Corrective action: a basic metabolic panel was added to the standing orders at that visit, and any dose change will be followed by a check at two weeks

Orders and referrals without results in the record

VisitTypeItemStatusDetail
2026-04-22
Progress note 02 (C-CDA)
ImagingKidney biopsyOrderedBooked in two days
2026-04-22
Progress note 02 (C-CDA)
Medication safetyPregnancy test and contraception before mycophenolateOrderedPregnancy test negative today; intrauterine system booked
2026-04-29
Progress note 03 (C-CDA)
Medication safetyHydroxychloroquine baseline eye examinationOrderedOphthalmology booked in two months
2026-10-05
Progress note 06 (C-CDA)
PreventionCervical cancer screeningOrderedCytology with HPV testing today, yearly while immunosuppressed

Evidence to check

Retrospective claims (R)

ClaimStatementCertainty
CLM-0011Physician authors attribute her hip disease to avascular necrosis of the femoral head from steroid treatment, and suggest that her jaw may have been affected in the same way.probable
CLM-0012Physician authors suggest from her letters and photographs that she may have had a malar facial rash early in her illness and the hand deformities of Jaccoud arthropathy.possible

Sensitive claims

None.

Diagnoses not confirmed

None.

Notes to read

Every note in the record, with its type. All clinical content is synthetic.

Abnormal results

DateResultValueFlag
2026-04-13Hemoglobin11 g/dL (low)Low
2026-04-13White cell count3.3 10*3/uL (low)Low
2026-04-13Lymphocytes0.8 10*3/uL (low)Low
2026-04-13Platelets138 10*3/uL (low)Low
2026-04-13Albumin3.3 g/dL (low)Low
2026-04-13ESR52 mm/h (high)High
2026-04-13CRP0.6 mg/dL (high)High
2026-04-13Urine protein-to-creatinine ratio1.6 g/g (high)High
2026-04-13Urine red cells18 /[HPF] (high)High
2026-04-22ANA titer (HEp-2 immunofluorescence)640 (high)High
2026-04-22Anti-dsDNA186 [IU]/mL (high)High
2026-04-22Anti-Sm42 U/mL (high)High
2026-04-22Complement C362 mg/dL (low)Low
2026-04-22Complement C48 mg/dL (low)Low
2026-04-22Urine protein-to-creatinine ratio1.8 g/g (high)High
2026-04-22Urine red cells22 /[HPF] (high)High
2026-04-29Hemoglobin11.2 g/dL (low)Low
2026-04-29White cell count3.6 10*3/uL (low)Low
2026-04-29Lymphocytes0.9 10*3/uL (low)Low
2026-04-2925-hydroxyvitamin D26 ng/mL (low)Low
2026-07-27Urine protein-to-creatinine ratio0.9 g/g (high)High
2026-07-27Urine red cells6 /[HPF] (high)High
2026-07-27Anti-dsDNA72 [IU]/mL (high)High
2026-07-27Complement C384 mg/dL (low)Low
2026-07-27Total cholesterol212 mg/dL (high)High
2026-07-27LDL cholesterol128 mg/dL (high)High
2026-10-26Urine protein-to-creatinine ratio0.35 g/g (high)High
2026-10-26Anti-dsDNA38 [IU]/mL (high)High